Difference between revisions of "Part:BBa K3718001"
Line 1: Line 1:
 
<h1> Transmembrane receptor with Customizable VHH region </h1>
 
<h1> Transmembrane receptor with Customizable VHH region </h1>
  
−
<p>Our Modular Receptor Platform (MRP) is designed according to the paper published in 2017.  The modular biosensor is composed of the <I>E. coli</I> CadC DNA binding domain, a juxtamembrane bridge region, an artificial 16-Leucine transmembrane region and a transmembrane receptor with customizable VHH region, which is a restriction site. </p>
+
<p>Our Modular Receptor Platform (MRP) is designed according to the paper published in 2017.  The modular biosensor is composed of the <I>E. coli</I> CadC DNA binding domain, a juxtamembrane bridge region, an artificial 16-Leucine transmembrane region, and a transmembrane receptor with customizable VHH region, which is a restriction site. </p>
  
−
<p>When the nanobody binds the target, dimerization of the protein CadC domains occur. As a result, this allows the binding of the pCadBA operon region and transcription downstream is promoted at the same time. </p>
+
<p>When the nanobody binds the target, dimerization of the protein CadC domains occurs. As a result, this allows the binding of the pCadBA operon region, and transcription downstream is promoted at the same time. </p>
  
−
<p>The VHH region has high flexible posibilities as it can be customized for binding with different targets, so that any specific targets with single-domain antibodies available are potentially ligand candidates for this receptor. </p>
+
<p>The VHH region has high flexible possibilities as it can be customised for binding with different targets, so that any specific targets with single-domain antibodies available are potentially ligand candidates for this receptor. </p>
  
−
<p>Users can add their own antibody VHH region after the transmembrane region DNA via restriction ligation. The KasI restriction site, together with sequence GCC, is added at the C-terminus of the transmembrane region. The addition of the restriction site is 3 bp. Therefore, the coding region, which includes the user’s VHH, is in-frame. A minimum addition of nucleotides is added in order to reduce any effect of the additional codon to the coding region. At the same time, KasI recognizes a 6bp site, so that the chances of having the cut site in other regions of the user's DNA are relatively low.</p>
+
<p>Users can add their own antibody VHH region after the transmembrane region DNA via restriction ligation. The KasI restriction site, together with sequence GCC, is added at the C-terminus of the transmembrane region. The addition of the restriction site is 3 bp. Therefore, the coding region, which includes the user’s VHH, is in-frame. A minimum addition of nucleotides is added in order to reduce any effect of the additional codon to the coding region. At the same time, KasI recognizes a 6bp site, so that the chances of having the cut site in other regions of the user's DNA are relatively low.</p>
 +
 
 +
<!-- Add more about the biology of this part here
 +
===Usage and Biology===
 +
 
 +
<!-- -->
 +
<span class='h3bb'>Sequence and Features</span>
 +
<partinfo>BBa_K3718001 SequenceAndFeatures</partinfo>
 +
 
 +
 
 +
<!-- Uncomment this to enable Functional Parameter display
 +
===Functional Parameters===
 +
<partinfo>BBa_K3718001 parameters</partinfo>
 +
<!-- -->

Revision as of 08:52, 14 October 2021

Transmembrane receptor with Customizable VHH region

Our Modular Receptor Platform (MRP) is designed according to the paper published in 2017. The modular biosensor is composed of the E. coli CadC DNA binding domain, a juxtamembrane bridge region, an artificial 16-Leucine transmembrane region, and a transmembrane receptor with customizable VHH region, which is a restriction site.

When the nanobody binds the target, dimerization of the protein CadC domains occurs. As a result, this allows the binding of the pCadBA operon region, and transcription downstream is promoted at the same time.

The VHH region has high flexible possibilities as it can be customised for binding with different targets, so that any specific targets with single-domain antibodies available are potentially ligand candidates for this receptor.

Users can add their own antibody VHH region after the transmembrane region DNA via restriction ligation. The KasI restriction site, together with sequence GCC, is added at the C-terminus of the transmembrane region. The addition of the restriction site is 3 bp. Therefore, the coding region, which includes the user’s VHH, is in-frame. A minimum addition of nucleotides is added in order to reduce any effect of the additional codon to the coding region. At the same time, KasI recognizes a 6bp site, so that the chances of having the cut site in other regions of the user's DNA are relatively low.

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal prefix found in sequence at 1
    Illegal suffix found in sequence at 563
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 1
    Illegal SpeI site found at 564
    Illegal PstI site found at 578
    Illegal NotI site found at 7
    Illegal NotI site found at 571
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 1
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal prefix found in sequence at 1
    Illegal suffix found in sequence at 564
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal prefix found in sequence at 1
    Illegal XbaI site found at 16
    Illegal SpeI site found at 564
    Illegal PstI site found at 578
  • 1000
    COMPATIBLE WITH RFC[1000]